- What is the most appropriate adjustment to his therapy?
Answer: Provide a small increase in the total weekly warfarin dose and recheck in 1-2 weeks.
The patient's INR of 2.2 is subtherapeutic for his high-risk indication (mechanical mitral valve, target 2.5-3.5). Given that he is asymptomatic and the value is only slightly below range, a modest increase in the total weekly dose (e.g., 5-10%) is the most appropriate course of action, with a follow-up INR check to assess the response. Holding a dose (A) or giving vitamin K (B) is for supratherapeutic INRs. Continuing the current dose (C) is inappropriate as it leaves the patient with inadequate protection against thromboembolism.
- What is the most appropriate immediate action regarding his warfarin therapy?
Answer: Administer a low dose of oral vitamin K and hold the next 1-2 doses of warfarin.
The patient's INR is supratherapeutic (4.8) but he is not actively bleeding. This is likely due to a well-known interaction between warfarin and trimethoprim-sulfamethoxazole, which inhibits warfarin metabolism. The appropriate management for an INR between 4.5 and 10 without bleeding is to hold the next 1-2 doses of warfarin and consider a small dose of oral vitamin K to facilitate a more rapid reduction in INR. Increasing the dose would be dangerous. Continuing the current dose is inappropriate given the elevated INR. Fresh frozen plasma is reserved for major, life-threatening bleeding.
- Which monitoring plan is most appropriate for his warfarin therapy upon initiation of amiodarone?
Answer: Proactively decrease the weekly warfarin dose by 25-50% and check INR within one week.
Amiodarone is a potent inhibitor of several cytochrome P450 enzymes, including CYP2C9, which is the primary enzyme responsible for metabolizing the more potent S-isomer of warfarin. This interaction leads to a significant increase in INR and bleeding risk. The standard of care is to anticipate this interaction by proactively reducing the warfarin dose (typically by 25-50%) and monitoring the INR closely (e.g., within 3-7 days) after starting amiodarone. Monitoring LFTs is important for amiodarone but does not address the INR interaction. Increasing the dose would be dangerous. Switching to a DOAC is a complex decision and not the immediate management step.
- What is the most appropriate action based on this trend in renal function?
Answer: Discontinue vancomycin and switch to linezolid.
The patient is experiencing progressive acute kidney injury (AKI), as evidenced by the serum creatinine more than doubling from baseline. This is a significant sign of vancomycin-induced nephrotoxicity. While dose adjustment (C) is an option for mild SCr increases, a rapid and significant rise like this often warrants discontinuing the offending agent if a suitable alternative exists. Linezolid is an appropriate alternative for many vancomycin indications. Simply giving fluids (B) is insufficient for established nephrotoxicity. Peak levels (D) are not routinely monitored for vancomycin and are not useful for managing nephrotoxicity; trough levels and renal function are key.
- In addition to monitoring for nephrotoxicity via BUN and creatinine, which two electrolyte disturbances are the most likely contributors to this arrhythmia?
Answer: Hypokalemia and hypomagnesemia
Amphotericin B is well-known for causing significant renal toxicity, which includes electrolyte wasting. It commonly causes profound hypokalemia and hypomagnesemia by increasing distal tubular membrane permeability. Both of these electrolyte abnormalities are highly pro-arrhythmic and are the most likely cause of the patient's PVCs. The other electrolyte combinations are not characteristic adverse effects of amphotericin B.
- In addition to a serum digoxin level, which lab value is most critical to assess to evaluate the risk and severity of digoxin toxicity in this patient?
Answer: Serum potassium
Hypokalemia significantly sensitizes the myocardium to the effects of digoxin, increasing the risk of toxicity even at therapeutic drug levels. The patient is on furosemide, which causes potassium wasting, and has worsening renal function, which impairs digoxin clearance. This combination makes assessing the serum potassium level critically important. While BUN reflects renal function and hypercalcemia can also potentiate digoxin toxicity, hypokalemia is a more common and potent precipitant of toxicity, especially in this clinical context.
- Which single laboratory test is most crucial to emergently evaluate for a common adverse effect of her new medication?
Answer: Serum sodium concentration
Carbamazepine is a well-known cause of the Syndrome of Inappropriate Antidiuretic Hormone (SIADH), which leads to water retention and dilutional hyponatremia. The symptoms of lethargy and disorientation in an elderly patient are classic manifestations of hyponatremia. While monitoring CBC (for aplastic anemia), LFTs, and drug levels are all part of routine carbamazepine management, the acute neurological symptoms make checking the serum sodium the most critical emergent test.
- Based on this interpretation of the patient's renal function, what is the most appropriate next step?
Answer: Calculate a reduced dose or select an extended interval regimen according to protocol.
The calculated CrCl of 35 mL/min is below the protocol's threshold of 50 mL/min, indicating that a dose adjustment is necessary to prevent drug accumulation and toxicity (nephrotoxicity and ototoxicity). The appropriate action is to use this calculated value to determine a reduced dose or an extended dosing interval. Relying on SCr alone (A) is misleading in the elderly, as muscle mass is decreased. A 24-hour urine collection (B) is time-consuming and not necessary for initial dosing adjustments. Aminoglycosides are not absolutely contraindicated (D) but require careful dosing in renal impairment.
- Which is the best interpretation of these lab results in the context of her new medication?
Answer: The observed changes are an expected pharmacologic effect of lisinopril and therapy can be continued with monitoring.
Initiation of an ACE inhibitor like lisinopril commonly causes a modest increase in serum creatinine (up to 30% from baseline) and potassium due to its hemodynamic effects on the glomerulus (efferent arteriole vasodilation). An increase from 1.4 to 1.7 mg/dL (approx. 21%) and a potassium level at the upper end of normal (5.2 mEq/L) fall within the expected and acceptable range. Therefore, the medication can be continued with continued monitoring. Discontinuation is not warranted for this modest change. While the BUN is elevated, it is consistent with the SCr change from the ACE inhibitor and CKD; there are no clear signs of dehydration. The sodium level is normal.
- For which of the following anticoagulants is the interpretation of his renal function labs most critical for determining if the drug can be used at all?
Answer: Dabigatran
Dabigatran is heavily reliant on renal clearance (approximately 80%). It is contraindicated in the United States for patients with a CrCl < 30 mL/min for the treatment of non-valvular atrial fibrillation. Therefore, interpreting the CrCl of 25 mL/min is critical because it excludes dabigatran as a therapeutic option. While rivaroxaban and apixaban also require dose adjustments for renal impairment and have restrictions, they can often be used with caution at this level of renal function. Warfarin dosing is guided by INR, not directly by CrCl, although renal impairment can increase bleeding risk.
- According to current FDA guidelines, at what estimated glomerular filtration rate (eGFR) is initiating metformin therapy contraindicated and continuation of therapy should be re-evaluated?
Answer: eGFR < 30 mL/min/1.73 m²
Current guidelines state that metformin is contraindicated in patients with an eGFR below 30 mL/min/1.73 m² due to the increased risk of lactic acidosis. For patients with an eGFR between 30 and 45 mL/min/1.73 m², initiating metformin is not recommended, and for those already on the drug, the risks and benefits should be assessed, and a dose reduction may be necessary. An eGFR < 60 is a point for increased monitoring, but not a contraindication. An eGFR < 15 represents end-stage renal disease, where metformin is definitively contraindicated, but the critical threshold for action is 30.
- Given the clinical presentation and ECG findings, which lab abnormality should be prioritized for correction to prevent life-threatening arrhythmias?
Answer: Hypomagnesemia, because it must be corrected to allow for effective potassium repletion.
While both hypokalemia and hypomagnesemia are present and contribute to cardiac arrhythmias, significant hypomagnesemia causes renal potassium wasting and makes cellular repletion of potassium difficult. Correcting the magnesium level first is often necessary for the effective treatment of concurrent hypokalemia. Therefore, prioritizing the correction of hypomagnesemia is the crucial first step to stabilize the patient's electrolyte balance and reduce arrhythmia risk. His sodium is normal and calcium is normal.
- A patient with a history of DVT is on apixaban. A review of their lab trends reveals the following: Baseline SCr: 0.9 mg/dL; 6 months: 1.2 mg/dL; 12 months: 1.6 mg/dL. What is the most significant clinical concern related to this trend and their anticoagulant therapy?
Answer: The patient is at increased risk of bleeding due to drug accumulation.
The serum creatinine is showing a consistent upward trend, indicating worsening renal function. Apixaban is partially cleared by the kidneys. As renal function declines, the drug can accumulate, leading to supratherapeutic levels and a significantly increased risk of bleeding. The risk is for over-anticoagulation, not under-anticoagulation. While some drugs cause nephrotoxicity, DOACs are not a common cause; the worsening renal function is more likely from other comorbidities. The trend clearly shows worsening, not improving, renal function.
- Which medication is the most likely contributor to his hyperkalemia?
Answer: Spironolactone, due to its antagonism of aldosterone receptors.
Spironolactone is a potassium-sparing diuretic that works by antagonizing aldosterone in the collecting ducts. This action leads to sodium and water excretion but potassium retention, frequently causing hyperkalemia. Furosemide is a loop diuretic that causes potassium wasting (hypokalemia), so it would counteract, not cause, the hyperkalemia. While hepatorenal syndrome can cause renal dysfunction and electrolyte abnormalities, the most direct and potent cause of hyperkalemia in his regimen is spironolactone.
- What is the most probable cause of the new lab abnormalities?
Answer: Calcineurin inhibitor (tacrolimus) toxicity.
Tacrolimus, a calcineurin inhibitor, is known to cause both nephrotoxicity (presenting as a rise in creatinine) and hyperkalemia. The patient's tacrolimus level is supratherapeutic (11 ng/mL), which strongly suggests that the drug's toxicity is the cause of the acute kidney injury and hyperkalemia. Acute rejection is less likely with a high tacrolimus level. Mycophenolate is not typically associated with these specific effects. Dehydration could cause a rise in creatinine but is less likely to cause such a significant degree of hyperkalemia in this context.
- An ECG is performed. Which acute electrolyte abnormality is the most likely underlying cause of his symptoms?
Answer: Hyperkalemia
This patient is on three medications that can cause hyperkalemia. Lisinopril (an ACE inhibitor) and spironolactone (a potassium-sparing diuretic) both increase potassium levels. Trimethoprim, a component of the antibiotic, also has a potassium-sparing effect similar to amiloride, further increasing the risk. The combination of these three agents in an elderly patient makes severe hyperkalemia a very high probability, which can manifest as weakness and life-threatening cardiac arrhythmias/palpitations.
- Which combination of lab abnormalities is most likely to be found, explaining her clinical deterioration?
Answer: Increased BUN, increased SCr, and hyperkalemia
This patient is experiencing the 'triple whammy' effect. The ACE inhibitor (lisinopril) dilates the efferent arteriole, the diuretic (furosemide) causes volume depletion, and the NSAID (ibuprofen) constricts the afferent arteriole. This combination severely reduces glomerular filtration pressure, leading to acute kidney injury (increased BUN and SCr). The reduced GFR, combined with the effect of the ACE inhibitor, also impairs potassium excretion, leading to hyperkalemia. These effects cause sodium and water retention, worsening her heart failure.
- What is the most accurate explanation for the patient's presentation and lab findings?
Answer: Hydrochlorothiazide-induced hyponatremia led to increased renal reabsorption of lithium.
Thiazide diuretics like hydrochlorothiazide induce a mild volume depletion and increase sodium excretion. The kidneys compensate by increasing reabsorption of sodium in the proximal tubule. Because lithium is handled similarly to sodium in the proximal tubule, its reabsorption is also increased, leading to decreased clearance and elevated serum levels, causing toxicity. The hyponatremia is a direct effect of the thiazide, which then precipitates the lithium toxicity. Lithium itself can cause nephrogenic diabetes insipidus (not SIADH), and dilution from polydipsia would lower, not raise, the lithium level.
- A patient is started on hydrochlorothiazide 25 mg daily for uncomplicated hypertension. After four weeks of therapy, which of the following patterns of change in laboratory values is most consistent with the known metabolic effects of this drug?
Answer: Decreased serum potassium, increased serum calcium, increased serum glucose
Thiazide diuretics like hydrochlorothiazide have a characteristic metabolic profile. They block the Na-Cl cotransporter in the distal convoluted tubule, which leads to increased potassium excretion (hypokalemia). They also increase calcium reabsorption in the distal tubule (hypercalcemia). Additionally, they can impair insulin release and increase insulin resistance, leading to hyperglycemia. Therefore, the combination of hypokalemia, hypercalcemia, and hyperglycemia is the expected pattern.
